Literature DB >> 2739350

Platelet factor 4 and the response to plasma exchange in the treatment of thrombotic thrombocytopenic purpura.

G Wiedemann1, I Kantner, M Schenke, E Schulz, T Wagner.   

Abstract

We report two patients with thrombotic thrombocytopenic purpura who were subjected to plasma exchange. In one case, the plasma levels of platelet factor 4, measured shortly after plasma exchange, increased significantly during plasma exchange. This was followed, however, by a failure to respond to therapy. Repeated plasmapheresis over 3 weeks gave no therapeutic benefit and reversible deep coma occurred. This patient recovered completely after treatment with vincristine. In the second patient, a decline in platelet factor 4 was observed after plasma exchange. This was accompanied by improvement of the patient's condition and a slow rise in platelet count. Plasma exchange was again carried out in this patient because of a recurrence of thrombotic thrombocytopenic purpura 3 years later; again decreased platelet factor 4 plasma levels were observed after plasma exchange and again a therapeutic response followed. Platelet factor 4, therefore, seems to be an effective and early index for the therapeutic benefit of plasma exchange in thrombotic thrombocytopenic purpura.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2739350     DOI: 10.1007/bf01719782

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  21 in total

1.  Disseminated arteriolar and capillary platelet thrombosis; a morphologic study of its histogenesis.

Authors:  I GORE
Journal:  Am J Pathol       Date:  1950-01       Impact factor: 4.307

2.  Thrombotic thrombocytopenic purpura; treatment with antiplatelet agents.

Authors:  G B Faguet; M B King
Journal:  Am J Med Sci       Date:  1974-08       Impact factor: 2.378

3.  Coagulation studies in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura.

Authors:  M Ekberg; I M Nilsson; T Denneberg
Journal:  Acta Med Scand       Date:  1974-11

4.  Treatment of thrombotic thrombocytopenic purpura with antiplatelet drugs.

Authors:  J Amir; S Krauss
Journal:  Blood       Date:  1973-07       Impact factor: 22.113

5.  Splenectomy, steroids, and dextran 70 in thrombotic thrombocytopenic purpura.

Authors:  J Cuttner
Journal:  JAMA       Date:  1974-01-28       Impact factor: 56.272

6.  Prostacyclin therapy of thrombotic thrombocytopenic purpura.

Authors:  G T Budd; R M Bukowski; F V Lucas; A E Cato; D M Cocchetto
Journal:  Lancet       Date:  1980-10-25       Impact factor: 79.321

7.  Treatment of thrombotic thrombocytopenic purpura with plasma.

Authors:  J J Byrnes; M Khurana
Journal:  N Engl J Med       Date:  1977-12-22       Impact factor: 91.245

8.  A platelet aggregating factor in thrombotic thrombocytopenic purpura: initial activity, fluctuations, and removal by plasma exchange.

Authors:  C V Hussey; L L Hause; J L Gottschall; T Anderson
Journal:  Thromb Res       Date:  1986-11-01       Impact factor: 3.944

9.  Clinical use of beta-thromboglobulin levels in diagnosing and treating consumptive and immune thrombocytopenia.

Authors:  M D Rubenstein; R T Wall
Journal:  Am J Hematol       Date:  1981-06       Impact factor: 10.047

10.  [Thrombotic thrombocytopenic purpura].

Authors:  C Aul; R E Scharf; T Königshausen; W Schneider
Journal:  Klin Wochenschr       Date:  1985-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.